碩貝德(300322.SZ):2022年度預虧6000萬元-6900萬元 同比盈轉虧
格隆匯1月20日丨碩貝德(300322.SZ)公佈2022年度業績預吿,報吿期歸屬於上市公司股東的淨利潤虧損6000萬元—6900萬元,同比盈轉虧;扣除非經常性損益後的淨利潤虧損7000萬元—7900萬元。
報吿期內,受疫情及外部環境影響,消費電子行業需求下行,公司指紋模組及終端天線業務銷售收入較上年同期下滑,淨利潤較上年同期下降。新能源相關產線尚處於投入階段,暫未形成規模效應,亦對公司淨利潤產生一定的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.